American Pharmaceutical Partners Inc (Schaumburg, Ill) recently announced FDA approval to launch Piperacillin for Injection USP, the generic equivalent of Wyeth?s Pipracil. Piperacillin is a third-generation antibiotic indicated for the treatment of serious infections caused by designated susceptible microorganisms such as Pseudomonas aeruginosa. This antibiotic is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. These microorganisms are found in a variety of conditions, including intra-abdominal infections, urinary tract infections, gynecologic infections, septicemia, lower respiratory tract infections, skin and skin-structure infections, bone and joint infections, and uncomplicated gonoccocal urethritis. For more information, visit www.appdrugs.com.